Next Article in Journal
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab
Next Article in Special Issue
Post-Translational Modifications in Tumor-Associated Antigens as a Platform for Novel Immuno-Oncology Therapies
Previous Article in Journal
Correction: Lee et al. Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. Cancers 2022, 14, 2659
Previous Article in Special Issue
The Immune Contexture of Liposarcoma and Its Clinical Implications
 
 
Review
Peer-Review Record

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes

Cancers 2022, 14(22), 5656; https://doi.org/10.3390/cancers14225656
by Olga Kouroukli 1, Argiris Symeonidis 2, Periklis Foukas 3, Myrto-Kalliopi Maragkou 4 and Eleni P. Kourea 5,*
Reviewer 1: Anonymous
Reviewer 2:
Cancers 2022, 14(22), 5656; https://doi.org/10.3390/cancers14225656
Submission received: 29 October 2022 / Revised: 11 November 2022 / Accepted: 15 November 2022 / Published: 17 November 2022
(This article belongs to the Special Issue Cancers Precision Immunotherapy)

Round 1

Reviewer 1 Report

This is a very nice, well written, comprehensive review on various aspects of immune dysregulation in the BM microenvironment in MDS. It covers a big body of the literature on both innate and adaptive immune responses throughout all the spectrum, from normal hematopoiesis, aging, CHIP, to low and high risk MDS, and their role in disease initiation, bone marrow failure, immune evasion and progression. A few points :
1. Although the title of the section "5q- syndrome as a paradigm of immune dysregulation in MDS initiation" is  nice and accurate, I feel it has been used in other reviews, too. I would recommend it should be changed, especially the word "paradigm". 

2. A molecule with a significant role in MDS that has been left out of this review is HMGB1. HMGB1 has been repeatedly reported to be elevated in MDS and is now under clinical trial.

3. Another part that has not been covered at all is therapeutic approaches targeting dysregulated immune pathways in MDS- of course this itself could be the topic of a separate review, but I feel that either as an additional small paragraph/section, or throughout the text, where relevant, would elevate this manuscript. I don't consider this change necessary though.

Author Response

We sincerely thank the reviewer for the constructive comments, that help improve our manuscript. The following changes are made with respect to the reviewer's comments:

  1. In the title of paragraph 5.1 the word "paradigm" is substituted by "representative example".
  2. A paragraph (5.3) is added with a brief report on HMGB1, and its involvement in MDS.
  3. A brief paragraph (6) is inserted just before the conclusions, selectively refering to the therapeutic implications of targeting elements of the immune microenvironment in MDS.

Reviewer 2 Report

Review article is well-organized and written.  The figures are extremely well done and complement the text nicely.    Nice comprehensive review of the BM immune microenvironment.   

Author Response

We thank the reviewer for the kind and generous comments.

Back to TopTop